SCP
SUPN icon

Seizert Capital Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Seizert Capital Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,141
Closed -$254K – 224
2020
Q1 		$254K Buy
+14,141
New +$297K 0.02% 164

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Seizert Capital Partners's SUPN Position: Q2 2020 in Review

Seizert Capital Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 14,141 shares — an estimated $254K sold.

Seizert Capital Partners first reported a position in SUPN in Q1 2020 and held it in 1 quarter. The position peaked at $254K in Q1 2020. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

  • Seizert Capital Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Seizert Capital Partners sold 14,141 Supernus Pharmaceuticals shares in Q2 2020, an estimated $254K.
  • Seizert Capital Partners first reported a position in Supernus Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Seizert Capital Partners's Supernus Pharmaceuticals position peaked at $254K in Q1 2020.
  • 218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Seizert Capital Partners's 13F filing for Q2 2020, filed 6 Aug 2020.